Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $440000.0.

  • Celldex Therapeutics' Capital Expenditures fell 1926.61% to $440000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 1968.29%. This contributed to the annual value of $1.9 million for FY2024, which is 555.56% up from last year.
  • As of Q3 2025, Celldex Therapeutics' Capital Expenditures stood at $440000.0, which was down 1926.61% from $728000.0 recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Capital Expenditures high stood at $756000.0 for Q4 2024, and its period low was $143000.0 during Q2 2021.
  • For the 5-year period, Celldex Therapeutics' Capital Expenditures averaged around $434052.6, with its median value being $410000.0 (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 8428.57% in 2021, then soared by 37062.94% in 2022.
  • Over the past 5 years, Celldex Therapeutics' Capital Expenditures (Quarter) stood at $354000.0 in 2021, then crashed by 33.62% to $235000.0 in 2022, then surged by 183.4% to $666000.0 in 2023, then rose by 13.51% to $756000.0 in 2024, then plummeted by 41.8% to $440000.0 in 2025.
  • Its Capital Expenditures stands at $440000.0 for Q3 2025, versus $728000.0 for Q2 2025 and $265000.0 for Q1 2025.